Efferon NEO

CE-marked, single-use pediatric hemoadsorption cartridge with an LPS-selective ligand on a macroporous hypercrosslinked polymeric sorbent – designed for simultaneous extracorporeal removal of bacterial endotoxin and excess inflammatory mediators.

Pediatric sepsis and septic shock can rapidly progress through endotoxin-driven inflammation and excessive cytokine release.
Efferon NEO is a purpose-built pediatric hemoadsorption cartridge with a reduced 30 mL blood filling volume. It simultaneously removes endotoxin and inflammatory mediators, with clinical data demonstrating improved haemodynamic stability, faster organ recovery, and earlier weaning from intensive-care support.

Dual-target blood purification – Simultaneous removal of bacterial endotoxin and excess cytokines.
Reduced inflammatory burden – Significant decreases in CRP, IL-6, and TNF-α.
Faster organ recovery – Associated with improved pSOFA scores and resolution of multiple organ dysfunction.
Earlier support withdrawal – Faster weaning from vasopressors and mechanical ventilation.
Improved clinical outcomes – Lower 28-day mortality was observed in the LASSO NEO controlled study.

Reduced 30 mL blood filling volume for pediatric use.
Weight-adjusted blood flow of 3-7 mL/min/kg.
Ready-to-use, sterile, pyrogen-free, single-use cartridge.
Isolated hemoadsorption or integration with RRT, ECMO, and CPB.
CE-marked under EU MDR.

Designed for pediatric patients with sepsis and septic shock where endotoxin and excessive inflammatory mediators contribute to haemodynamic instability and multiple organ dysfunction. Efferon NEO enables multimodal blood purification through a pediatric-adapted extracorporeal circuit.

CE-marked, single-use pediatric hemoadsorption cartridge with an LPS-selective ligand on a macroporous hypercrosslinked polymeric sorbent – designed for simultaneous extracorporeal removal of bacterial endotoxin and excess inflammatory mediators.

Connect with our clinical team.